|
|
|
|
2-methoxyestradiol
2ME2. A drug that prevents the formation of new blood vessels that tumors need in order to grow. It is derived from estrogen and belongs to the family of drugs called angiogenesis inhibitors. (National Cancer Institute)
EntreMed to Present at SG Cowen Health Care Conference Mar 8, 2005
Panzem® (2-Methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in clinical trials for advanced cancer, as well as in preclinical ... Yahoo News (press release)
EntreMed Reports Fourth Quarter and Year-End 2004 Financial ... Mar 9, 2005
Panzem(R) (2-Methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for advanced cancer, as well as in preclinical ... mysan.de (Pressemitteilung),
EntreMed Reports on Anticancer Progress at Angiogenesis Symposium Feb 14, 2005
...cgi-bin/prnh/20010620/ENMDLOGO ) EntreMed scientists presented posters on three of its oncology programs including: 1) Panzem(R) NCD (2-methoxyestradiol or 2ME2 ... PR Newswire (press release)
EntreMed Reports on Anticancer Progress at Angiogenesis ... Feb 14, 2005
EntreMed scientists presented posters on three of its oncology programs including: 1) Panzem(R) NCD (2-methoxyestradiol or 2ME2), the Company’s lead product ... mysan.de (Pressemitteilung),
EntreMed to Participate in Anti-Angiogenesis Panel at BIO CEO ... Feb 18, 2005
EntreMed's lead compound, Panzem(R) NCD (2-methoxyestradiol or 2ME2) and its second generation 2ME2 analog, ENMD-1198, both work through multiple mechanisms ... PharmaLive.com (press release),
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
Drug stops tumours rebuilding lifelines May 17, 2004
YC-1 has not yet been tested in humans. But another drug, 2-methoxyestradiol, has been shown to inhibit HIF-1 production in human cancer patients. ... Nature.com
Resources from the National Cancer Institute on 2-methoxyestradiol:
Cancer.gov Phase I Study of 2-Methoxyestradiol in Patients With Advanced Solid Tumors. ... Patients
receive oral 2-methoxyestradiol (2-ME) once daily. ...
Cancer.gov - Angiogenesis Inhibitors in Clinical Trials Drugs that inhibit endothelial cells directly: Drug, List of Active Clinical Trials.
2-methoxyestradiol (2-ME), List of 2-ME trials. CC-5013 (Thalidomide Analog), ...
Center for Cancer Research - Staff Pages ..., Trial Number 01C0256, Directed by William Dahut Title: A Phase I Trial of 2-Methoxyestradiol
(2ME2), (NSC-659853) an Angiogenesis Inhibitor, in Patients ...
Center for Cancer Research - Staff Pages 23: 315-8, 2003. [PubMed Abstract]. 14) Lakhani NJ, Sarkar MA, Venitz J, Figg
WD: 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. ...
NUTRITIONAL GENOMICS AND PROTEOMICS IN CANCER PREVENTION ... File Format: PDF/Adobe Acrobat - View as HTML ... retinoic acid [RA], dehydroepiandrosterone [DHEA]); cyclooxygenase (COX-2 inhibitors,
selenium); angiogenesis (endostatin, 2-methoxyestradiol [2- ME]); and ...
Cancer.gov - Dictionary Also called magnetic resonance spectroscopic imaging and proton magnetic
resonance spectroscopic imaging. 2-methoxyestradiol 2ME2. ...
Center for Cancer Research - Staff Pages ...histone-deacetylase inhibitors (MS-275, phenylbutyrate, phenylacetate and the cyclic
depsipeptide FK228), antiangiogenic agents (2-methoxyestradiol and CC-5013 ...
Center for Cancer Research - Staff Pages In addition we are currently conducting two phase I trials of oral anti-angiogenic
agents (2-methoxyestradiol and CC-5013), which we believe are well suited ...
|
|
|
